Myriad Genetics (MYGN) Chief Commercial Officer granted 226,804 RSUs

Rhea-AI Filing Summary

Donnelly Brian J reported acquisition or exercise transactions in this Form 4 filing.

MYRIAD GENETICS INC Chief Commercial Officer Brian J. Donnelly reported an equity compensation grant of 226,804 shares of common stock in the form of time-based restricted stock units at a price of $0.00 per share.

Each restricted stock unit represents a contingent right to receive one share of common stock and will vest in three equal annual installments beginning on the first anniversary of the grant date. Following this award, Donnelly holds 624,338 shares of common stock directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Donnelly Brian J

Role Chief Commerical Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	226,804	$0.00	--

Holdings After Transaction: Common Stock — 624,338 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Donnelly Brian J

(Last) (First) (Middle)

322 NORTH 2200 WEST

(Street)

SALT LAKE CITY UT 84116

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MYRIAD GENETICS INC [ MYGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commerical Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/12/2026		A		226,804(1)	A	$0	624,338	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Consists of time-based restricted stock units granted pursuant to the Issuer's 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock and vests in three equal annual installments beginning on the first anniversary of the grant date.

Remarks:

	By: Justin Hunter For: Brian J. Donnelly	03/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Myriad Genetics (MYGN) disclose about Brian Donnelly in this Form 4?

Myriad Genetics reported that Chief Commercial Officer Brian J. Donnelly received 226,804 time-based restricted stock units as an equity award, increasing his direct holdings to 624,338 common shares as of the reported transaction date.

How many Myriad Genetics (MYGN) shares were granted to Brian Donnelly?

Brian Donnelly was granted 226,804 restricted stock units, each representing one share of Myriad Genetics common stock. The grant was reported at a price of $0.00 per share as part of his equity compensation package.

How do Brian Donnelly’s restricted stock units in MYGN vest over time?

The 226,804 restricted stock units granted to Brian Donnelly vest in three equal annual installments. Vesting begins on the first anniversary of the grant date, with one-third of the award vesting each year thereafter, subject to the plan’s terms.

Is Brian Donnelly’s Myriad Genetics Form 4 transaction a market purchase or sale?

The reported Form 4 transaction is an equity grant, not a market trade. Brian Donnelly acquired 226,804 restricted stock units at $0.00 per share as compensation, rather than buying or selling shares on the open market.

What is Brian Donnelly’s total Myriad Genetics (MYGN) ownership after this grant?

After receiving the 226,804 restricted stock units, Brian Donnelly’s direct holdings increased to 624,338 shares of Myriad Genetics common stock, as reported in the Form 4 following the grant transaction.

Under which equity plan were Brian Donnelly’s MYGN restricted stock units granted?

Brian Donnelly’s 226,804 restricted stock units were granted under Myriad Genetics’ 2017 Employee, Director and Consultant Equity Incentive Plan, which governs the terms, vesting schedule, and conditions for these equity awards.